Trials / Completed
CompletedNCT02996097
Fractional Laser Assisted Steroid Therapy vs Intralesional Steroids in the Treatment of Keloids
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Johns Hopkins University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the effects of fractional carbon dioxide (CO2) laser therapy immediately followed by intralesional steroid therapy against intralesional steroid therapy alone for the treatment of keloids.
Detailed description
Intralesional corticosteroids remain the gold standard treatment for keloids. However, more effective therapies are desperately desired. Ablative fractional laser (AFL) treatment facilitates delivery of intralesional steroid more deeply and uniformly into the skin by creating vertical channels. Recent studies have showed that fractional laser assisted steroid therapy can be effective in the treatment of keloids. However the studies are lacking in comparing this treatment modality to the gold standard of intralesional steroids.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | The Lutronic electronic carbon dioxide (eCO2) Plus laser system | CO2 ablative laser plus intralesional triamcinolone acetonide A topical EMLA cream or tetracaine 7%/lidocaine 23% will be applied to the both treatment sites and after sufficient anesthesia is attained, one keloid will be treated with the fractional CO2 laser using standard protocol as practiced in our clinics followed by intralesional triamcinolone acetonide. One lesion would be treated with fractional CO2 ablative laser followed with intralesional triamcinolone acetonide at 4 weeks intervals |
| DRUG | Intralesional Triamcinolone Acetonide |
Timeline
- Start date
- 2016-04-01
- Primary completion
- 2018-06-15
- Completion
- 2018-06-15
- First posted
- 2016-12-19
- Last updated
- 2020-12-17
- Results posted
- 2019-04-25
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02996097. Inclusion in this directory is not an endorsement.